Search results
Vertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals strikes at the core of serious diseases to change people's lives – learn about our mission, values and recognition.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Jan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.
Latest Press Releases. Jun 21 2024. Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions. Read More.
May 6, 2024 · BOSTON -- (BUSINESS WIRE)--May 6, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
Get the latest Vertex Pharmaceuticals Incorporated (VRTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and...
Dec 13, 2023 · BOSTON -- (BUSINESS WIRE)--Dec. 13, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
